Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
6997 results about "Elution" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In analytical and organic chemistry, elution is the process of extracting one material from another by washing with a solvent; as in washing of loaded ion-exchange resins to remove captured ions. In a liquid chromatography experiment, for example, an analyte is generally adsorbed, or "bound to", an adsorbent in a liquid chromatography column. The adsorbent, a solid phase (stationary phase), is a powder which is coated onto a solid support. Based on an adsorbent's composition, it can have varying affinities to "hold" onto other molecules—forming a thin film on its surface. Elution then is the process of removing analytes from the adsorbent by running a solvent, called an "eluent", past the adsorbent/analyte complex. As the solvent molecules "elute", or travel down through the chromatography column, they can either pass by the adsorbent/analyte complex or they can displace the analyte by binding to the adsorbent in its place. After the solvent molecules displace the analyte, the analyte can be carried out of the column for analysis. This is why as the mobile phase passes out of the column, it typically flows into a detector or is collected for compositional analysis.
High-temperature characterization of polymers
InactiveUS6260407B1Avoid backlogImprove throughputSequential/parallel process reactionsComponent separationElutionChromatography column
Rapid characterization and screening of polymer samples to determine average molecular weight, molecular weight distribution and other properties is disclosed. Rapid flow characterization systems and methods, including liquid chromatography and flow-injection analysis systems and methods are preferably employed. High throughput, automated sampling systems and methods, high-temperature characterization systems and methods, and rapid, indirect calibration compositions and methods are also disclosed. In preferred high-temperature embodiments, the polymer sample is maintained at a temperature of not less than about 75° C. during sample preparation, loading into a liquid chromatography or flow-injection analysis system, injection into a mobile phase of a liquid chromatography or flow-injection analysis system, and/or elution from chromatographic column. The described methods, systems, and device have primary applications in combinatorial polymer research and in industrial process control.
Owner:INTERMOLECULAR
Method for separating analyte from a sample
InactiveUS6893879B2Improve elution efficiencyBioreactor/fermenter combinationsBiological substance pretreatmentsSporeChemical reaction
An analyte is separated from a fluid sample by introducing the sample into a cartridge having an extraction chamber containing capture material for capturing the analyte. The sample is forced to flow through the extraction chamber to capture the analyte with the capture material in the extraction chamber. The captured analyte is then eluted from the extraction chamber by forcing an elution fluid to flow through the extraction chamber. The cartridge may optionally include a lysing region for lysing sample components (e.g., cells spores, or microorganisms), a waste chamber for storing waste fluid, and reaction or detection chambers for chemically reacting or detecting the eluted analyte.
Owner:CEPHEID INC
Microfluidic nucleic acid analysis
ActiveUS20050053952A1Bioreactor/fermenter combinationsBiological substance pretreatmentsCDNA libraryCells isolation
Nucleic acid from cells and viruses sampled from a variety of environments may purified and expressed utilizing microfluidic techniques. In accordance with one embodiment of the present invention, individual or small groups of cells or viruses may be isolated in microfluidic chambers by dilution, sorting, and/or segmentation. The isolated cells or viruses may be lysed directly in the microfluidic chamber, and the resulting nucleic acid purified by exposure to affinity beads. Subsequent elution of the purified nucleic acid may be followed by ligation and cell transformation, all within the same microfluidic chip. In one specific application, cell isolation, lysis, and nucleic acid purification may be performed utilizing a highly parallelized microfluidic architecture to construct gDNA and cDNA libraries.
Owner:CALIFORNIA INST OF TECH
Microfluidic device for purifying a biological component using magnetic beads
InactiveUS20070184463A1Bioreactor/fermenter combinationsBiological substance pretreatmentsMagnetic beadElution
A method of purifying a biological component found in a biological sample by extracting the biological component from the biological sample. The method is performed using a microfluidic device having at least one well for receiving the biological sample and at least one channel for introducing and removing fluids. A plurality of magnetic beads having a factor with an affinity for the biological component is introduced to the well together with a suitable biological sample. The biological sample is manipulated to release the biological component in proximity to the magnetic beads which are then segregated within the well while removing the biological sample. An elution solution for the biological component is introduced to the well and the elution solution together with the biological component are withdrawn therefrom.
Owner:CAPLIPER LIFE SCI INC +1
Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation
ActiveUS20110104061A1Improve concentrationOrganic active ingredientsBacterial antigen ingredientsRenal HypertensionsCvd risk
Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
Owner:MERCATOR MEDSYST
Topographic coatings and coating methods for medical devices
InactiveUS20050228477A1Easy to operateImprove adhesionStentsPretreated surfacesInsertion stentElution
Medical devices having topographic coatings are provided. The topographic coatings have regions of high and low elevation and may be composed of polymers, metals, ceramics, proteins and other biocompatible materials. Such topographic coatings facilitate the deposition, elution, and protection of therapeutic agents on the medical device, manipulation of the medical device, and other purposes. In particularly preferred embodiments, the medical device comprises a stent for vascular implantation.
Owner:XTENT INC
Drug delivery to a joint
A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the device releases the drug into the synovial fluid of the synovial joint, and so that agitation of the synovial fluid facilitates elution of the drug from the drug release device.
Owner:NEW YORK SOC FOR THE RUPTURED & CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY
Irrigated Catheter with Improved fluid flow
An irrigated catheter with uniform cooling and/or uniform fluid distribution in longitudinally spaced apart elution holes by varying the diameter of a fluid delivery lumen. A number of elution holes are provided in a tip region of a catheter body, and these elution holes are in fluid communication with the lumen through ducts. The fluid deliver lumen has may provided with a flow constrictor to restrict flow of fluid towards the distal region.
Owner:ST JUDE MEDICAL ATRIAL FIBRILLATION DIV
Medical devices with nanoporous layers and topcoats
The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is placed on the surface of a medical device, then one component of the mixture or alloy is generally removed without generally removing the other components of the mixture or alloy. In some embodiments, a porous layer is adapted for bonding non-metallic coating, including drug eluting polymeric coatings. A porous layer may have a random pore structure or an oriented or directional grain porous structure. One embodiment of the invention relates to medical devices, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents. The invention also includes methods, devices, and specifications for loading of drugs and other therapeutic agents into nanoporous coatings.
Owner:MEDTRONIC VASCULAR INC +1
Method for loading nanoporous layers with therapeutic agent
The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is placed on the surface of a medical device, then one component of the mixture or alloy is generally removed without generally removing the other components of the mixture or alloy. In some embodiments, a porous layer is adapted for bonding non-metallic coating, including drug eluting polymeric coatings. A porous layer may have a random pore structure or an oriented or directional grain porous structure. One embodiment of the invention relates to medical devices, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents. The invention also includes methods, devices, and specifications for loading of drugs and other therapeutic agents into nanoporous coatings.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND +1
Isolation of proteins
InactiveUS20050176122A1Other chemical processesSolid sorbent liquid separationSpecial classCarboxylic acid
The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts, in the binding process and preferably also the use of small amounts of organic solvents in the elution process. The solid phase matrices, preferably epichlorohydrin activated agarose matricees, are functionalised with mono- or bicyclic aromatic or heteroaromatic ligands (molecular weight: at the most 500 Dalton) which, preferably, comprises an acidic substituent, e.g. a carboxylic acid. The matrices utilised show excellent properties in a “Standard Immunoglobulin Binding Test” and in a “Monoclonal Antibody Array Binding Test” with respect to binding efficiency and purity, and are stable in 1M NaOH.Owner:UPFRONT CHROMATOGRAPHY
High sensitivity quantitation of peptides by mass spectrometry
InactiveUS20040072251A1Loss of substantial specific binding capacityReduce complexitySamplingComponent separationChemical structureProtein target
The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample
Owner:ANDERSON FORSCHUNG GROUP
Isolation of proteins
InactiveUS6919436B2Other chemical processesSolid sorbent liquid separationSpecial classCarboxylic acid
The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts, in the binding process and preferably also the use of small amounts of organic solvents in the elution process. The solid phase matrices, preferably epichlorohydrin activiated agarose matricees, are functionalised with mono- or bicyclic aromatic or heteroaromatic ligands (molecular weight: at the most 500 Dalton) which, preferably, comprises an acidic substituent, e.g. a carboxylic acid. The matrices utilised show excellent properties in a “Standard Immunoglobulin Binding Test” and in a “Monoclonal Antibody Array Binding Test” with respect to binding efficiency and purity, and are stable in 1M NaOH.
Owner:UPFRONT CHROMATOGRAPHY
Purification of proteins
ActiveUS20080255027A1Ion-exchange process apparatusPeptide/protein ingredientsElutionProcess conditions
The present invention relates to a selectively soluble polymer capable of binding to a desired biomolecules in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and / or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired biomolecule (protein, polypeptide, etc) and remains capable of binding to that biomolecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed.
Owner:MILLIPORE CORP
Method for separating analyte from a sample
InactiveUS20050194316A1Simple designImprove efficiencyBioreactor/fermenter combinationsBiological substance pretreatmentsAnalyteElution
An analyte is separated from a fluid sample by introducing the sample into a cartridge having a sample port and a first flow path extending from the sample port. The first flow path includes an extraction chamber containing a solid support for capturing the analyte from the sample. The cartridge has a second flow path for eluting the captured analyte from the extraction chamber, the second flow diverging from the first flow path after passing through the extraction chamber. The sample is forced to flow through the extraction chamber and into a waste chamber, thereby capturing the analyte with the solid support as the sample flows through the extraction chamber. The captured analyte is then eluted from the extraction chamber by forcing an elution fluid to flow through the extraction chamber and along the second flow path.
Owner:CEPHEID INC
Method for measuring substance and testing piece
InactiveUS7153696B2High measurement accuracyHigh measurement sensitivityAnalysis using chemical indicatorsMaterial analysis by observing effect on chemical indicatorDiffusionChemical reaction
A method of measuring an analyte, comprising a step of measuring a detectable substance by using a reaction system including a formation reaction of the detectable substance based on a chemical reaction of the analyte contained in a sample, wherein a layered inorganic compound is caused to exist in the reaction system including the formation reaction of the detectable substance, whereby high-sensitivity measurement is made possible, the detectable substance can be stabilized to improve accuracy of the measurement, a rate of a chemical reaction is increased to enable quick measurement, and high-sensitivity measurement is made possible even in a reaction system which forms an insoluble substance. Also, it can be provided an analytical testing piece for measuring an analyte, by measuring a detectable substance by using a reaction system including a formation reaction of the detectable substance based on a chemical reaction of the analyte contained in a sample, wherein the testing piece comprises at least one test portion having a detection portion for detecting the detectable substance and contains a layered inorganic compound at least in the test portion, whereby diffusion and elution of a dyestuff or the like is prevented, more sensitive and accurate simple analysis is made possible, and easy handling is possible.
Owner:ARKRAY INC
Antibody purification by cation exchange chromatography
A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.
Owner:GENENTECH INC
Polyoxyalkylene polyols, derivatives thereof, and process for producing the polyoxyalkylene polyols
The present invention is a polyoxyalkylene polyol, its manufacture method, and derivatives, wherein: it is obtained using a phosphazenium compound as a catalyst; the hydroxyl value is 2~200 mgKOH/g; total degree of unsaturation is 0.0001~0.07 meq./g; the head-to-tail bond selectivity of the polyoxyalkylene polyol is 95 mole %; and when the maximum height of the peak of GPC elution curve is set to be 100%, W20 is defined as the peak width at the 20% peak height, and W80 is defined as the peak width at 80% peak height, the ratio of W20/W80 is 1.5 or greater, and less than 3.
Owner:MITSUI CHEM & SKC POLYURETHANES INC
Process for chromatographic separation of peptides and nucleic acid, and new high affinity ion exchange matrix
InactiveUS6090288ACation exchanger materialsComponent separationChromatographic separationTransferrin
PCT No. PCT/SE97/00237 Sec. 371 Date Dec. 29, 1998 Sec. 102(e) Date Dec. 29, 1998 PCT Filed Feb. 14, 1997 PCT Pub. No. WO97/29825 PCT Pub. Date Aug. 21, 1997Process for separating off a peptide or a nucleic acid by an anion exchanger (I) characterized in that a) the anion exchanger (I) exhibits ligands, which (i) contain a primary, secondary or tertiary amino group and (ii) are covalently bound to an organic polymer (matrix), b) there on a carbon atom at a distance of 2 or 3 atoms away from an amino nitrogen in the ligands is a hydroxyl group or a primary, secondary or tertiary amino group, and c) the maximum elution ionic strength in the pH range 2-14 for at least one of the proteins transferrin, ovalbumin 1, ovalbumin 2, beta -lactoglobulin 1 and beta -lactoglobulin 2 on the anion exchanger is higher than the elution ionic strength required for a quaternary comparative ion exchanger.
Owner:GE HEALTHCARE BIOPROCESS R&D
Treatment of hypertension by renal vascular delivery of guanethidine
Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
Owner:MERCATOR MEDSYST
Embolic filter device and related systems and methods
An embolic filter system is provided that has a bioactive surface, such as locally on the surface itself or via elution into surrounding environs, and such as to debulk its filtered contents or prevent thrombosis or thromboemboli. An engineered wall provides for enhanced porosity for improved combination of blood flow through the filter and size of particulate that may be captured. Manufacturing methods are provided for improved filter assemblies, and a tether system is provided for improved in-situ deployment. A proximal filter assembly is used to debulk contents of a distal embolic filter assembly before it is removed from the patient.
Owner:EMERGE MEDSYST
Polymeric composite including nanoparticle filler
InactiveUS20070106006A1Increase potential environmental impactReduce load levelHalloysiteNanoparticle
Disclosed is a novel polymeric composite including a nanoparticle filler and method for the production thereof. More particularly, the present invention provides a novel halloysite nanoparticle filler which has the generally cylindrical or tubular (e.g. rolled scroll-like shape), in which the mean outer diameter of the filler particle is typically less than about 500 nm. The filler is effectively employed in a polymer composite in which the advantages of the tubular nanoparticle filler are provided (e.g., reinforcement, flame retardant, chemical agent elution, etc.) with improved or equivalent mechanical performance of the composite (e.g., strength and ductility).
Owner:NATURALNANO CORP
Controllable drug releasing gradient coatings for medical devices
InactiveUS20070078513A1Prevent vessel occlusionSlow and more prolonged releaseOrganic active ingredientsSurgerySolubilityMedicine
Implantable medical devices having a polymer gradient coating capable of controllably releasing at least one pharmaceutical compound to a localized area are disclosed. More specifically, the gradient coatings comprise at least two layers where at least one of these layers incorporates at least one pharmaceutical compound. Each of the layers of the gradient coating has at least one physical property affecting the releasability of the pharmaceutical compound incorporated therein that differs from that of at least one other layer. These physical properties include, but are not limited to, solubility constants, molecular weights, elution profiles, and bonding strengths.
Owner:MEDTRONIC VASCULAR INC
Method and apparatus for spray processing of porous medical devices
InactiveUS20070036905A1Minimize contaminationMinimize oxidationMolten spray coatingPretreated surfacesPorous substrateThermal spraying
Thermal spray processing and cold spray processing are utilized to manufacture porous starting materials (such as tube stock, wire and substrate sheets) from biocompatible metals, metal alloys, ceramics and polymers that may be further processed into porous medical devices, such as stents. The spray processes are also used to form porous coatings on consolidated biocompatible medical devices. The porous substrates and coatings may be used as a reservoir to hold a drug or therapeutic agent for elution in the body. The spray-formed porous substrates and coatings may be functionally graded to allow direct control of drug elution without an additional polymer topcoat. The spray processes are also used to apply the drug or agent to the porous substrate or coating when drug or agent is robust enough to withstand the temperatures and velocities of the spray process with minimal degradation.
Owner:ABBOTT CARDIOVASCULAR
High throughput autosampler
InactiveUS20050194318A1Improve throughputMinimizes sample carryoverSequential/parallel process reactionsComponent separationAutosamplerHigh flux
An auto-injection system provides high throughput screening of fluidic samples. A sample injection valve has a first position which applies a reduced pressure to a sample sipper tube for aspirating a fluidic sample into the sample sipper tube, and a second position which delivers the fluidic sample to a sample supply loop. A column control valve has a first position which delivers the fluidic sample from the sample supply loop to a sample chromatography column, and a second position which reverses direction of fluid flow through the sample chromatography column to deliver the fluidic sample to a sample analyzer. A wash control valve has a first position which supplies a wash buffer solution to the sample chromatography column in a forward fluid flow direction, and a second position which supplies elution solvent to flush the sample supply loop.
Owner:AGILENT TECH INC
Ectopic leaching restoring device and restoring method for chromic slag polluted soil
ActiveCN102601106AContinuous operationRealize emergency handlingContaminated soil reclamationAutomatic controlSlag
The invention relates to an ectopic leaching restoring device and a restoring method for chromic slag polluted soil. The device is provided with an integrated soil leaching and dewatering system and mainly comprises a feeding system, a soil leaching-dewatering system, a waste gas treating system, an elution collecting treating system and an automatics control system. The chromic slag polluted soil firstly enters a reaction tank leaching section through the feeding system; a chrome-containing component in the soil is transferred into a liquid phase of a leaching agent; the liquid phase is rotated following a spiral stirring thruster; a muddy water mixture is conveyed into a reaction tank dewatering section; the filtrate is discharged through a tank wall with a water-permeable filtering function; the remained soil is conveyed to a mud discharging device following the rotating of the spiral stirring thruster; and lastly, the soil after being leached and dewatered is discharged. The device provided by the invention has the advantages that a power source is utilized to realize the soil leaching and muddy water separating, the energy consumption is low, the structure is simple, the use is convenient, the treating efficiency is high, and the purified degree of the polluted soil after being treated by using the device is above 85%.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI
Liquid to liquid biological particle concentrator with disposable fluid path
ActiveUS8584535B2Reduce liquid volumeQuick focusSemi-permeable membranesMicrobiological testing/measurementFiltrationElution
Highly efficient and rapid filtration-based concentration devices, systems and methods are disclosed with sample fluidic lines and a filter packaged in a disposable tip which concentrate biological particles that are suspended in liquid from a dilute feed suspension. A sample concentrate or retentate suspension is retained while eliminating the separated fluid in a separate flow stream. The concentrate is then dispensed from the disposable tip in a set volume of elution fluid. Suspended biological particles include such materials as proteins / toxins, viruses, DNA, and / or bacteria in the size range of approximately 0.001 micron to 20 microns diameter. Concentration of these particles is advantageous for detection of target particles in a dilute suspension, because concentrating them into a small volume makes them easier to detect. All conduits by which the disposable tip attaches to the instrument are combined into a single connection point on the upper end of the tip.
Owner:INNOVAPREP
Method for separating an analyte from a sample
InactiveUS7914994B2Simple designImprove efficiencyBioreactor/fermenter combinationsHeating or cooling apparatusAnalyteElution
An analyte is separated from a fluid sample by introducing the sample into a cartridge having a sample port and a first flow path extending from the sample port. The first flow path includes an extraction chamber containing a solid support for capturing the analyte from the sample. The cartridge has a second flow path for eluting the captured analyte from the extraction chamber, the second flow diverging from the first flow path after passing through the extraction chamber. The sample is forced to flow through the extraction chamber and into a waste chamber, thereby capturing the analyte with the solid support as the sample flows through the extraction chamber. The captured analyte is then eluted from the extraction chamber by forcing an elution fluid to flow through the extraction chamber and along the second flow path.
Owner:CEPHEID INC
Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same
InactiveUS6184023B1Avoid stickingInhibit productionBacteriaHydrolasesChondroitinase ABCConcentration gradient
A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant.
Owner:SEIKAGAKU KOGYO CO LTD
Nanoporous layers using thermal dealloying
The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is placed on the surface of a medical device, then one component of the mixture or alloy is generally removed without generally removing the other components of the mixture or alloy. In some embodiments, a porous layer is adapted for bonding non-metallic coating, including drug eluting polymeric coatings. A porous layer may have a random pore structure or an oriented or directional grain porous structure. One embodiment of the invention relates to medical devices, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents. The invention also includes methods, devices, and specifications for loading of drugs and other therapeutic agents into nanoporous coatings.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap